SecBot SecBot

RGNX

REGENXBIO Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· CIK 0001590877 Biotech & Drug Discovery
$7.32 −0.32 (−4.19%)
Nov 16 4:00 PM ET · prev $7.64
Market cap
$531.0M
Small cap
Consensus
Buy
89% Buy or better · 18 analysts
Median target
$19.00
+160% · range $12.00–42.00
1 year
−34.3%
from $11.14 · Nov 17
30 days
+2.4%
from $7.15
52-week range
$5.65–15.98
−54% from high · low May 18
Avg volume 20D
1.27M
shares / day
Short interest
10.18M
≈15.4% of shares · +1.4%
Days to cover
8.3
at average volume
Insider net
+$9.4K
1 buyer · 1 seller · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
14
analyzed by SecBot
SecBot read MIXED 7 reports · 90 days
Balance 1 bearish · 1 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 4/7

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersMIXED

    1 insider bought $949.4K at an average $9.25. 1 insider sold $940.0K. Price is 21% below their cost.

  • InstitutionsBULLISH

    Q3 2026: 33 added (0 new), 15 trimmed or exited.

  • AnalystsBULLISH

    16 of 18 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest +1.4% to 10.18M shares. 8.3 days to cover, ≈15.4% of shares.

  • TrendRANGE

    4% below its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Nov 5.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
JPMORGAN CHASE & COADD3,562,841$26.5M
VANGUARD PORTFOLIO MANAGEMENT LLCADD2,646,375$19.9M
GEODE CAPITAL MANAGEMENT, LLCADD1,582,758$11.9M
Nuveen, LLCADD1,007,749$7.6M
MARSHALL WACE, LLPTRIM878,610$6.6M
Hudson Bay Capital Management LPADD440,000$3.3M
VANGUARD FIDUCIARY TRUST COADD430,784$3.2M
FRANKLIN TEMPLETON INCDOUBLED266,663$2.1M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

18 analysts
Buy 89% rate it Buy or better
Strong Buy6Buy10Hold2Sell0Strong Sell0
12-month targets · 10 analysts

Price is below the lowest target. Median implies +160%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Oct 5, 2026Mizuho
INITIATE
INITIATEOutperform
Aug 25, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Aug 25, 2026Baird
MAINTAIN
MAINTAINOutperform
Aug 10, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Aug 7, 2026Barclays
DOWNGRADE
DOWNGRADEEqual-Weight
Jun 24, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Washington

Corporate Lobbying

15 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Insider ledger

Form 4
$949.4K
bought · 1 insider
$940.0K
sold · 1 insider
−20.9%
vs their $9.25 cost
DateInsiderTypeValue
Nov 1, 2026
Christmas Patrick J.
Chief Strategy & Legal Officer
Nov 1, 2026
AWARD34,722 sh
Nov 1, 2026
Chan Mitchell
Chief Financial Officer
Nov 1, 2026
AWARD24,305 sh
Nov 1, 2026
Malzahn Craig
Chief Technology Officer
Nov 1, 2026
AWARD27,777 sh
Nov 1, 2026
PAKOLA STEVE
Chief Medical Officer
Nov 1, 2026
AWARD34,722 sh
Sep 1, 2026
Malzahn Craig
Chief Technology Officer
Sep 1, 2026
TAX W/H$2.2K
Sep 1, 2026
Chan Mitchell
Chief Financial Officer
Sep 1, 2026
TAX W/H$45.7K
Aug 27, 2026
Ciongoli Gregory Austin
Director
Aug 27, 2026
BUY$499.7K
Aug 26, 2026
Ciongoli Gregory Austin
Director
Aug 26, 2026
BUY$449.7K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Reddit
Recent posts
All social signals and their track records

Short side

FINRA· Oct 30, 2026
10,179,714
shares short
+1.4%
vs prior settlement
8.3
days to cover
≈15.4%
of shares outstanding
Trading halts
Aug 24, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 10, 2026 SEC
State Street Corp. filed a new SC 13G disclosing a 4.8% passive stake in REGENXBIO Inc., confirming the position is…
SC 13G · Impact 3/10
Nov 5, 2026 SEC
REGENXBIO reported Q3 2026 revenue of $9.2M, well below the $10.7M consensus, and a GAAP net loss of $0.62 per share…
8-K · Impact 5/10
Nov 5, 2026 Earnings result
RGNX Q3 2026 Earnings: EPS $-0.62 (+52.8% vs est)
Nov 4, 2026 SEC
A small institutional cluster in RGNX shows mixed conviction: three asset managers added tiny positions (total $276K)…
INST-CLUSTER · Impact 2/10
Nov 1, 2026 Insider
Christmas Patrick J. was granted 34,722 shares
Chief Strategy & Legal Officer
Nov 1, 2026 Insider
Chan Mitchell was granted 24,305 shares
Chief Financial Officer
Nov 1, 2026 Insider
Malzahn Craig was granted 27,777 shares
Chief Technology Officer
Sep 30, 2026 Inst.
JPMORGAN CHASE & CO · ADD
3,562,841 shares ($26.5M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
4 drugs tracked · Drug pipeline →
Recent
Nov 5, 2026
Earnings result
RGNX Q3 2026 Earnings: EPS $-0.62 (+52.8% vs est)
Nov 3, 2026
Company news
REGENXBIO to Participate in Stifel 2026 Healthcare Conference
ROCKVILLE, Md., Nov. 3, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the Stifel 2026 Healthcare…
Oct 29, 2026
Earnings
REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights
ROCKVILLE, Md., Oct. 29, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday…
Oct 12, 2026
Press release
REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20
Event to include clinical program overview and perspectives from leading retina specialists ahead of topline pivotal data readout anticipated in 4Q…
Sep 30, 2026
Short interest
Short Interest: RGNX up 21% to 9.6M shares
Settlement 2026-09-30 | Days to cover: 5.99 | ≈14.56% of shares outstanding (est.)

SecBot reports

14 filings · 1 press release · 3 bullish · 2 bearish · 2 mixed · 7 neutral
All RGNX filing & press-release reports (15)